Drug Testing Guide: Panels, Specimen Types, Detection Windows, and the MRO Process

Educational guide · Reviewed June 2026 · By the Laboratories.org editorial team

Workplace drug tests screen urine, hair, oral fluid, or blood for the presence of drugs or their metabolites. The 5-panel urine test is the federal standard for DOT-regulated employers; private employers commonly use 10- or 12-panel versions for broader coverage. Understanding which panel you will face, how detection windows work, and how the Medical Review Officer (MRO) process protects your rights is useful for anyone preparing for pre-employment or ongoing workplace drug screening.

Panel types — 5, 10, and 12

A "panel" refers to the number of distinct drug classes included in a single screen. The 5-panel is the federal baseline mandated by law. Larger panels add prescription drug classes most commonly misused in workplace settings.

5-panel (Federal standard / DOT)

The foundational workplace panel mandated by federal regulations for DOT-regulated employers and federal agencies. Governed by 49 CFR Part 40 and HHS Mandatory Guidelines. Effective January 1, 2018, "Opiates" was renamed "Opioids" and expanded to include four semi-synthetic opioids (hydrocodone, hydromorphone, oxycodone, oxymorphone) — the panel now covers 14 individual analytes under 5 category headings.

Who uses it: Federal agencies, DOT-regulated employers (FMCSA trucking, FAA aviation, FRA rail, FTA transit, PHMSA pipeline, USCG maritime). Private employers who want the simplest, most defensible standard also commonly adopt the 5-panel.

SAMHSA immunoassay cutoff concentrations for the 5-panel (urine):

10-panel

The 10-panel builds on the DOT 5-panel with five additional substance classes, primarily addressing prescription drug misuse. It is not federally mandated and is used by non-DOT private employers who want broader coverage.

Non-DOT employers can customize the 10-panel — substituting propoxyphene or methaqualone for fentanyl, tramadol, or synthetic cannabinoids based on their workforce risk profile.

12-panel

An extension of the 10-panel adding two more drug classes. The 12-panel is not standardized — panel composition varies by testing vendor. Common additions include MDMA/ecstasy (sometimes listed separately), oxycodone (as a separate line even if present in the opioid group), buprenorphine (Suboxone — an opioid treatment drug), tricyclic antidepressants (TCAs), or fentanyl (increasingly added given the opioid crisis).

A common 12-panel includes: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine (or TCA), Cocaine, Ecstasy/MDMA, Marijuana/THC, Methadone, Methamphetamine, Opiates/Morphine, Oxycodone, and PCP. The 12-panel is used in broader pre-employment screening, healthcare, rehabilitation programs, legal and forensic settings, and some school testing programs.

Specimen types & detection windows

Urine is the dominant specimen for workplace drug testing, but hair, oral fluid, blood, and sweat patches each have distinct characteristics. The choice of specimen type determines both how far back in time use can be detected and how practically convenient the test is to collect.

Urine (most common)

Urine dominates workplace drug testing because of its high drug and metabolite concentrations, low cost, enormous detection menu (1,500+ substances), and ability to support multiple tests from a small sample. Collection requires a minimum of 30 mL (45 mL for DOT). A Chain of Custody Form (CCF) documents specimen identity from collection to lab. DOT and SAMHSA require specimen validity testing (SVT) — labs test for creatinine, specific gravity, pH, and oxidizing adulterants to detect dilution or substitution attempts. Negative results are typically reported within 24–48 hours. Non-negative results require GC-MS confirmation, adding 24–72 hours; total turnaround is approximately 3–5 business days.

Oral fluid / saliva

Oral fluid tests detect the parent drug (not just its metabolite), which means they can detect use within minutes to approximately 48 hours. This makes oral fluid useful for post-accident and reasonable-suspicion testing scenarios where recent or active impairment is the concern. SAMHSA issued Mandatory Guidelines for Oral Fluid (OFMG) effective October 2023, and DOT published a final rule allowing oral fluid as a second authorized specimen type for DOT-regulated testing. The short detection window is a limitation — oral fluid may miss use from several days prior.

Hair follicle

Drugs and metabolites from the bloodstream deposit in the hair shaft as it grows (approximately 1 cm per month). A standard 1.5-inch scalp sample reflects approximately 90 days of use history. Body hair grows more slowly and can reflect up to 12 months. Hair testing is very difficult to adulterate and is useful for identifying patterns of use over time rather than recent use. Key limitations: a 7–14 day lag exists before drugs appear in hair that has grown past the scalp; tests cannot detect very recent use; the test may be influenced by hair color (melanin content), hair texture, and chemical treatments such as bleaching or perming. Hair testing is not permitted for DOT-regulated testing. Some states restrict its use — California (AB 2188, effective January 1, 2024) bars employers from using hair or urine tests for marijuana in most hiring decisions.

Lab vs. instant tests; screen vs. confirmation; the MRO

Understanding how results are generated and reviewed protects both employers and employees. A confirmed positive from a certified laboratory is not the same as a final verified positive — the Medical Review Officer is the critical gatekeeper between the lab result and any employment action.

Lab-based testing (standard method)

1. Specimen collected at an authorized site with a Chain of Custody Form (CCF).
2. Specimen shipped to an HHS/SAMHSA-certified laboratory.
3. Lab performs an initial immunoassay screen (IA) — fast, high-throughput, antibody-based.
4. If the screen is negative, the result is reported (typically within 24–48 hours).
5. If non-negative (presumptive positive), the specimen is reflex-tested using GC-MS or LC-MS/MS confirmation.
6. Confirmed result is reviewed by the Medical Review Officer (MRO).
7. MRO-verified final result is reported to the employer's Designated Employer Representative (DER).

Instant / rapid / point-of-collection testing (POCT)

Rapid tests use FDA-cleared immunoassay devices (dipsticks or integrated collection cups) at the collection site — not a laboratory. Results appear as color-change lines within 5–10 minutes. Negative POCT results are typically final. Non-negative (presumptive positive) POCT results must be sent to a certified lab for GC-MS or LC-MS/MS confirmation before any employment action can be taken. POCT is not acceptable as a final positive for adverse employment action without laboratory confirmation, and is not permitted as the sole testing method for DOT-regulated programs.

Screen vs. confirmation testing

Initial screen (immunoassay): Detects drug class by antibody cross-reactivity. Designed for high sensitivity (few false negatives) but can cross-react with structurally similar compounds — some medications or foods can produce false positives on the screen alone. All presumptive non-negatives must be confirmed before any action is taken.

Confirmation — GC-MS and LC-MS/MS: Gas Chromatography–Mass Spectrometry (GC-MS) is the traditional gold standard for confirmation. It separates compounds by gas-phase chromatography, then identifies them by their unique mass spectral fingerprint. Liquid Chromatography–Mass Spectrometry/Mass Spectrometry (LC-MS/MS) is increasingly used for opioids, benzodiazepines, and buprenorphine. Both methods identify the exact substance and its concentration — not just a drug class. A confirmed positive at or above the cutoff concentration is reported as a positive.

Medical Review Officer (MRO)

The MRO is a licensed physician (MD or DO) who is the final reviewer of all laboratory-generated drug test results in a workplace testing program. The MRO is required under 49 CFR Part 40 for all DOT-regulated testing and is strongly recommended for all employment testing.

Core MRO functions:

• Quality assurance: Reviews chain-of-custody documentation, lab procedures, and CCF forms for every specimen. Can cancel a test if procedural errors compromise result integrity.
• Medical determination: For any confirmed positive, adulterated, substituted, or invalid result, the MRO contacts the donor directly (private medical interview) to determine whether a legitimate medical explanation exists — such as a valid prescription. If a valid prescription is verified with the prescribing physician, the result may be reported to the employer as negative.
• Result reporting: Reports the verified final result only to the employer's DER — not the donor's medical history. Ensures timely and confidential flow of results.

Detection windows by substance

Detection windows vary considerably by substance, specimen type, frequency of use, and individual metabolism. All figures below are approximations at standard SAMHSA cutoff concentrations for urine. Detection window also depends on dose, body fat percentage (THC is lipophilic and stored in fat tissue), urine pH, and hydration level.

For oral fluid, detection windows are much shorter — most substances are detectable for 5–48 hours. For hair, a standard 1.5-inch sample reflects approximately 90 days of use, but cannot detect recent use due to the 7–14 day lag before drugs appear in newly grown hair. Blood testing reflects current intoxication at the time of collection (8–12 hours for most drugs) and is used primarily in DUI enforcement and clinical settings.

Why people get tested

Drug testing occurs in several distinct contexts, each with its own legal framework and procedural requirements.

Pre-employment testing

The most common context. An employer screens a job candidate before extending an offer or before the first day. Typically triggered by a conditional job offer. Applicants in DOT-regulated roles cannot begin safety-sensitive work until a verified negative result is received.

Random testing

Employees are selected via a scientifically valid random mechanism so every employee has an equal chance of selection each cycle. Must be unannounced — employees report to collection without prior notice. DOT minimum rates for FMCSA-regulated employers: 25% of average number of drivers annually for drugs; 10% for alcohol. Random testing is the cornerstone of ongoing deterrence in safety-sensitive industries.

DOT-regulated testing (safety-sensitive functions)

DOT-regulated testing applies to employees in safety-sensitive roles under six DOT operating agencies: FMCSA (commercial motor vehicle drivers with CDL), FAA (pilots, air traffic controllers, aircraft mechanics, flight attendants), FRA (railroad engineers, conductors, dispatchers), FTA (mass transit vehicle operators, controllers, maintenance), PHMSA (pipeline operations), and USCG (commercial vessel crew).

Mandatory DOT testing triggers include: pre-employment, random, post-accident (after accidents meeting defined severity criteria), reasonable suspicion (based on specific documented observations of appearance or behavior suggesting impairment), return-to-duty (directly observed negative test after a substance abuse violation), and follow-up testing (minimum 6 tests in the first 12 months after return-to-duty; may continue up to 60 months).

Probation / court-ordered testing

Courts and probation officers order drug and alcohol testing as a condition of supervised release, probation, parole, or drug court participation. Frequency and panel type are determined by the court or probation officer. Refusal to test or a confirmed positive can constitute a probation violation, potentially resulting in revocation and incarceration.

SAMHSA-certified labs

The National Laboratory Certification Program (NLCP) is the HHS accreditation system for laboratories that test specimens for federal agency drug testing programs. It is administered under SAMHSA's Division of Workplace Programs (DWP). Authority derives from Section 503 of Public Law 100-71; HHS Mandatory Guidelines were most recently revised effective February 1, 2024 (urine) and October 10, 2023 (oral fluid).

Three certification tiers

• Urine laboratories — conduct all tests (initial screen + confirmatory) and report all results.
• Oral fluid laboratories — conduct all tests for oral fluid specimens.
• Instrumented Initial Test Facilities (IITFs) — for urine only; conduct initial screen and report only negatives and negative-dilutes; forward all non-negatives to a certified urine laboratory.

Certification requirements

Applicant labs must pass three consecutive rounds of performance testing (PT) with blind samples of known drug concentrations before certification. An on-site inspection occurs at the third PT round, with an additional inspection 3 months after initial certification. Ongoing requirements include quarterly maintenance PT and semi-annual maintenance inspections. Failed PT or inspections result in suspension or revocation of certification.

Why SAMHSA certification matters

• Legal defensibility: Only SAMHSA/HHS-certified labs meet the forensic toxicology standards required for results to hold up in court, administrative hearings, or employment disputes.
• Federal compliance: Required by law for all federal agency and DOT-regulated testing.
• Split specimen right: For federal and DOT testing, a confirmed positive gives the donor the right to request that the "B" split specimen be tested by a second, independently certified lab — providing an additional layer of protection against laboratory error.

Non-regulated employers who want legally defensible results should use SAMHSA-certified labs, or at minimum labs accredited by the College of American Pathologists (CAP). The current list of certified labs is published and maintained by SAMHSA.

Alcohol (EtG) testing

Standard workplace alcohol testing under DOT uses breath or saliva testing — not urine — to detect ethanol. The EtG (Ethyl Glucuronide) test is a separate, extended biomarker test used in sobriety monitoring contexts, not routine DOT testing.

DOT breath alcohol testing

DOT regulations require breath testing using an Evidential Breath Testing device (EBT) or saliva testing to detect ethanol. Breath alcohol tests measure Breath Alcohol Concentration (BrAC). DOT action levels: workers are prohibited from performing safety-sensitive functions at BrAC ≥ 0.04. At BrAC 0.02–0.039, the employee is removed from duty for at least 8 hours (no formal violation record). Must be conducted by a certified Breath Alcohol Technician (BAT) using a NHTSA-approved EBT device. Detection window for ethanol via breath: approximately 12–24 hours after the last drink.

EtG and EtS — extended alcohol biomarkers

Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS) are minor metabolites of ethanol detectable in urine long after ethanol itself has cleared.

EtG at high levels (>1,000 ng/mL) likely indicates same-day drinking or heavy drinking the previous day. A low positive (500–1,000 ng/mL) may indicate drinking within the previous 1–2 days, or light drinking within 24 hours. Importantly, EtG can occasionally produce low-level positives from incidental alcohol exposure — such as mouthwash, hand sanitizer, or certain foods — and must be interpreted in clinical context. EtG measures past alcohol consumption, not current impairment. A positive EtG does not indicate the person was impaired during work hours.

Use cases for EtG/EtS: Court-ordered sobriety monitoring (probation, drug court programs); return-to-duty follow-up monitoring for alcohol-related violations; employee assistance programs requiring abstinence verification; and some employers with strict zero-tolerance alcohol policies. EtG/EtS is not part of standard DOT alcohol testing, which uses breathalyzers.

How ordering works

Employer-initiated testing and direct-to-consumer individual testing follow similar processes, but with different authorization and result-reporting paths.

Employer / TPA ordering — lab-based workflow

The employer or third-party administrator (TPA) establishes an account with a certified testing provider (e.g., Quest Diagnostics or Labcorp). When a test is needed, the employer generates a test order — a Chain of Custody Form (CCF) or electronic CCF (eCCF) — with the employee's identifying information and test specifications. The donor takes this authorization to an authorized specimen collection site (Quest has 8,000+ collection sites nationwide; Labcorp has a similar network). The trained collector verifies the donor's identity with a government-issued photo ID, completes chain-of-custody documentation, and collects the specimen. The sealed specimen is shipped to the certified laboratory under chain-of-custody controls. Negative results are typically reported within 24–48 hours. Confirmed positives requiring MRO review take approximately 3–5 business days total.

Direct-to-consumer (individual) ordering

Individuals can order drug tests for personal purposes through services such as US Drug Test Centers, Health Street, or RequestATest:

1. Order and pay online; select the panel and specimen type.
2. Receive a lab requisition or pass code electronically.
3. Visit the nearest collection site in the provider's network (often 10,000–20,000 locations nationwide).
4. Provide specimen at the collection site.
5. Results delivered via secure online portal or email, typically with MRO review for non-negative results.